

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ACTAVIS LLC,  
Petitioner,

v.

ABRAXIS BIOSCIENCE, LLC,  
Patent Owner.

---

Case IPR2017-01103  
Patent 7,923,536

---

**PATENT OWNER'S MANDATORY NOTICES**

Abraxis BioScience, LLC, the Patent Owner, provides the following mandatory notices pursuant to 37 C.F.R. § 42.8.

**REAL PARTY-IN-INTEREST**

In accordance with 37 C.F.R. § 42.8(b)(1), Patent Owner identifies Abraxis Biosciences, LLC (“Abraxis”) and Celgene Corporation (“Celgene”) as real parties-in-interest. Celgene is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 86 Morris Avenue, Summit, New Jersey 07901. Abraxis is a wholly owned subsidiary of Celgene. Abraxis, a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 11755 Wilshire Boulevard, 20th Floor, Los Angeles, California 90025, is the owner of all right, title and interest in U.S. Patent No. 7,923,536 (“the ’536 Patent”) by virtue of an assignment from the inventors, Neil P. Desai, Patrick Soon-Shiong, and Vuong Trieu. The Assignment was recorded on January 26, 2011 at Reel 025703, Frame 0300.

**RELATED MATTERS**

Pursuant to 37 C.F.R. § 42.8(b)(2), Patent Owner identifies the following:

**A. Proceedings Before the USPTO Involving Related Patents**

- The ’536 Patent, which issued from U.S. Application Serial No. 12/758,413, is a continuation of the U.S. Application Serial No.

11/553,339, which issued as U.S. Patent No. 7,820,788 (“the ’788 Patent”). The ’788 Patent is the subject of IPR2017-001101.

- U.S. Patent No. 8,138,229 (“the ’229 Patent”), which issued from U.S. Application Serial No. 12/910,693, is a continuation of U.S. Application Serial No. 11/553,339, which issued as the ’788 Patent. The ’229 Patent is the subject of IPR2017-01104.

#### **B. Litigations Involving the Patent-at-Issue**

The ’536 Patent is the subject of the following pending litigations:

- *Abraxis Bioscience, LLC et al v. Actavis, LLC*, 2:16-cv-09074-JMV-MF (D.N.J. April 6, 2016).
- *Abraxis Bioscience, LLC et al v. Cipla Ltd.*, 2:16-cv-09074-JMV-MF (D.N.J. Dec. 7, 2016).

## **II. LEAD AND BACKUP COUNSEL AND SERVICE INFORMATION**

In accordance with 37 C.F.R. §§ 42.8(b)(3), 42.8(b)(4), and 42.10(a), Patent

Owner identifies the following lead and backup counsel and service information:

Lead counsel: J. Patrick Elsevier, Ph.D.(Reg. No. 44,668)  
Jones Day  
4655 Executive Drive, Suite 1500  
San Diego, CA 92121-3134  
Tel: (858) 314-1200  
Fax: (844) 345-3178  
Email: [jpelsevier@jonesday.com](mailto:jpelsevier@jonesday.com)

Backup counsel:

Anthony M. Insogna (Reg. No. 35,203) Jones Day 4655 Executive Drive, Suite 1500 San Diego, CA 92121-3134 Tel: (858) 314-1200 Fax: (844) 345-3178 Email: <a href="mailto:aminsogna@jonesday.com">aminsogna@jonesday.com</a>	Cary Miller, Ph.D. (Reg. No. 54,708) Jones Day 4655 Executive Drive, Suite 1500 San Diego, CA 92121-3134 Tel: (858) 314-1200 Fax: (844) 345-3178 Email: <a href="mailto:cmiller@jonesday.com">cmiller@jonesday.com</a>
Lisamarie LoGiudice, Ph.D. (Reg. No. 71,047) Jones Day 250 Vesey Street New York, NY 10281-1047 Tel: (212) 326-3939 Fax: (212) 755-7306 Email: <a href="mailto:llogiudice@jonesday.com">llogiudice@jonesday.com</a>	F. Dominic Cerrito (Reg. No. 38,100) Quinn Emanuel Urquhart & Sullivan, LLP 51 Madison Avenue, 22nd Floor New York, NY 10010 Tel: (212) 849-7112 Fax: (212) 849-7100 Email: <a href="mailto:nickcerrito@quinnemanuel.com">nickcerrito@quinnemanuel.com</a>
Andrew S. Chalson (pro hac vice) Quinn Emanuel Urquhart & Sullivan, LLP 51 Madison Avenue, 22nd Floor New York, NY 10010 Tel: (212) 849-7112 Fax: (212) 849-7100 Email: <a href="mailto:andrewchalson@quinnemanuel.com">andrewchalson@quinnemanuel.com</a>	Frank C. Calvosa (Reg. No. 69,064) Quinn Emanuel Urquhart & Sullivan, LLP 51 Madison Avenue, 22nd Floor New York, NY 10010 Tel: (212) 849-7112 Fax: (212) 849-7100 Email: <a href="mailto:frankcalvosa@quinnemanuel.com">frankcalvosa@quinnemanuel.com</a>

Patent Owner consents to electronic service by email.

Pursuant to 37 C.F.R. § 42.10(b), a Power of Attorney is being submitted to the Board herewith.

Respectfully submitted,

Dated: April 24, 2017

*/s/ J. Patrick Elsevier, Ph.D.* \_\_\_\_\_

J. Patrick Elsevier, Ph.D.

(Reg. No. 44,668)

Jones Day

4655 Executive Drive, Suite 1500

San Diego, CA 92121-3134

Tel: (858) 314-1200

Fax: (844) 345-3178

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.